LG Chem to get approval for sale of biosimilar Japanese etanercept ----------------------------------------- Thanks for watching video. Don't forget subscribe this channel: https://goo.gl/bBBK38
With biosimilar biological products moving from the lab to the marketplace, key policy and regulatory questions are being actively debated, with important implications for industry, patients, and the health care system. This discussion provides background on current policy and regulatory issues surrounding biosimilars. The panel discussion includes the following experts: Leah Christl, associate director for therapeutic biologics, The Food and Drug Administration (FDA) Barbara Finck, chief medical officer, Coherus Biosciences Brian Lehman, manager of pharmacy benefits and policy, Ohio Public Employees Retirement System (OPERS) Leigh Purvis, director of health services research, AARP Angus Worthing, rheumatologist and member of ACR Government Affairs Committee, American College of Rheumatology Sarah Dash of the Alliance for Health Reform moderates.
In this short video, PAREXEL expert Dr. Cecil Nick, Vice President-Biotechnology, compares current FDA & EMA requirements for biosimilars.
Lupin has formed a joint venture with Japanese pharma company Yoshindo to develop a robust pipeline of bio-similars for the market. This further strengthens its presence in the Japanese market. Priya Sheth shares a detailed report on the same. This video is originally sourced from Bloomberg TV India, you can watch it here: http://www.btvin.com/videos/watch/6811/Lupin-Inks-JV-With-Japan%27s-Yoshindo-
Get Full Details On: http://www.researchbeam.com/global-biologics-and-biosimilars-industry-2015-deep-research-report-market Global Biologics And Biosimilars Industry Size, Share, Market Trends, Growth, Analysis, Capacity, Production, Cost, Price, Profit, Production Value, Report 2015 Report Overview Research Beam adds a report titled “Global Biologics And Biosimilars Industry 2015 Deep Market Research Report” that provides detailed information of the Global Biologics And Biosimilars Industry. The report is an excellent piece of study for investors who are looking towards the market. For overview analysis, the report introduces Biologics And Biosimilars basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.For international and China market analysis, the report analyzes Biologics And Biosimilars markets in China and other countries or regions (such as US, Europe, Japan, etc.) by presenting research on global products of different types and applications, developments and trends of market, technology, competitive landscape, and leading suppliers’ and countries’ 2009-2014 capacity, production, cost, price, profit, production value, and gross margin. For leading suppliers, related information is listed as products, customers, application, capacity, market position, and company contact information, etc. 2015-2020 forecast on capacity, production, cost, price, profit, production value, and gross margin for these markets are also included. For technical data and manufacturing plants analysis, the report analyzes Biologics And Biosimilars leading suppliers on capacity, commercial production date, manufacturing plants distribution, R&D status, technology sources, and raw materials sources.
BIOSIMILARS- Regulatory Framework and Pipeline Analysis provides market dynamics, key players, therapy area, development phase, legal strategies, action mechanism, late stage products, competition prediction, indications, healthcare expenditure, trends, growth drivers, barriers, scope and a lot more.
AIRC TI AUGURA BUON 2016 影视财务报告 www.whyinvestin.com 是第一财经视频平台，在这里你可以很容易的通过视频描述了全球证券通过搜索。 有关视频： 我们相信，通过结合精确的选择财务数据的友好运动图形表示复杂的财务数据可能变得更加平易近人。为了保证最有效的信息准，我们吸引了来自本杰明·格雷厄姆著作“聪明的投资者”，经济哲学的支柱。 如果你是一家公司，在中国市场上市（香港或上海）想与Whyinvestin联系请发送电子邮件至：email@example.com VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances. Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein. DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements. EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness. FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com . Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein. Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade. COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner . Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article. If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email: firstname.lastname@example.org
Klaus Martin, Head Biopharmaceuticals in Polpharma Biologics talks about biosimilars market in Poland. He specifies it and underlines challenges that it still need to overcome. Klaus Martin, starszy dyrektor ds. produktów biotechnologicznych i rozwoju biznesu Polpharma Biologics opowiada o rynku produktów biopodobnych w Polsce. Charakteryzuje go, a także wymienia wyzwania, jakie wciąż stoją przed jego rozwojem. Więcej ciekawych publikacji odnajdziesz na portalu biotechnologia.pl ©Biotechnologia.pl/ Cebiotech.com
Biosimilar drugs for chronic illnesses including breast cancer which costs 30 to 40 percent lower than originator products are expected to flood the local market in 2016. These first Malaysian-made biosimilar products are also expected to hit the ASEAN market of Vietnam, the Philippines, Myanmar, Laos and Cambodia. All this, as a result of a joint venture between Inno Bio Ventures Sdn Bhd and Aryogen Biopharma. A biosimilar product is a copy of an original product which is worth between 20 and 30 million U-S dollars in the 5 ASEAN countries. They are now set to be commercialized. The four products are the Rituximab for treatment of non-Hodgkin lymphoma, rheumatoid arthritis, chronic lmphocytic and leukemia; Trastuzumab for HER2-positive breast cancer; Etanercept for rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondilytis; and Factor VII for haemophilia and congenital factor VII deficiency. The market value for the four originator products in the five countries was over US$20mil.
‘Truth is, Samsung, LG Chem and other Korean firms are merely warming up’ by BuzzStyle ‘Truth is, Samsung, LG Chem and other Korean firms are merely warming up’ by BuzzStyle On the eve of 1988’s scorching Summer Olympic Games in Seoul, we Brits could have bought any Korean car we liked; as long as it was a Hyundai, often featuring a nasty blue interior and an even nastier pea green paintjob. Rightly, we didn’t queue to buy ’em. Wind forward three decades and during this, the first week of the Winter Olympics in PyeongChang, just up the icy mountain road from Seoul, and Hyundais are selling big time to UK consumers. As are Kias. And with SsangYong SUVs also in the mix, the Koreans will again shift around 200,000 cars to Brits this year. Not bad. But nowhere near good enough for a still ambitious, if tiny, north east Asian country that already builds about the same number of cars annually (3.9 million) as the wobbly, considerably larger USA. • Winter car checklist: driving kit and best buysTruth is, the Koreans are merely warming up when it comes to this car building lark. The above established marques will continue to do their thing. But there’s no reason w... --------------------------------------------------------------- Thank you for watching! Don't forget subscribe this channel.